Novo Nordisk Partners with OpenAI on AI Integration

Danish pharmaceutical giant Novo Nordisk announced a partnership with OpenAI on Tuesday to integrate artificial intelligence across its operations, aiming to accelerate drug discovery and improve efficiency in delivering treatments for obesity and diabetes.

The collaboration will deploy OpenAI's technology to analyze complex datasets, identify promising drug candidates earlier, and streamline processes from research and development to manufacturing, supply chains, distribution, and commercial activities. Pilot programs have begun in research, manufacturing, and commercial teams, with full companywide integration targeted by the end of 2026. OpenAI will also provide training to enhance AI literacy among Novo Nordisk's global workforce, boosting productivity without plans to reduce current staff levels.

Novo Nordisk Chief Executive Officer Mike Doustdar emphasized the partnership's focus on augmentation rather than replacement. "The aim here is not replacing our scientists. It's about supercharging them," he said in an interview. He added that the initiative would help moderate the pace of future hiring by enabling employees to work faster and more effectively. Doustdar noted that...